Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

J Biol Chem. 2017 Mar 10;292(10):4359. doi: 10.1074/jbc.A117.553818.
No abstract available

Publication types

  • Published Erratum